Shield Therapeutics PLC
LSE:STX

Watchlist Manager
Shield Therapeutics PLC Logo
Shield Therapeutics PLC
LSE:STX
Watchlist
Price: 10.75 GBX 0.47% Market Closed
Market Cap: 114.1m GBP

Operating Margin

-0.4%
Current
Improving
by 2.1%
vs 3-y average of -2.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-0.4%
=
Operating Income
£-14.6m
/
Revenue
£41.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-0.4%
=
Operating Income
GBX-14.6m
/
Revenue
£41.5m

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Shield Therapeutics PLC
LSE:STX
112m GBP
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.6B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.4B USD
Loading...

Market Distribution

Lower than 85% of companies in United Kingdom
Percentile
15th
Based on 3 579 companies
15th percentile
-0.4%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

Shield Therapeutics PLC
Glance View

Market Cap
114.1m GBX
Industry
Pharmaceuticals

Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.

STX Intrinsic Value
20.05 GBX
Undervaluation 46%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-0.4%
=
Operating Income
£-14.6m
/
Revenue
£41.5m
What is Shield Therapeutics PLC's current Operating Margin?

The current Operating Margin for Shield Therapeutics PLC is -0.4%, which is above its 3-year median of -2.5%.

How has Operating Margin changed over time?

Over the last 3 years, Shield Therapeutics PLC’s Operating Margin has increased from -7.6% to -0.4%. During this period, it reached a low of -35.2% on Jun 30, 2025 and a high of -0.7% on Dec 31, 2024.

Back to Top